Table 1 Basic and clinical characteristics of patients at baseline.
| Total patient population (n = 121) | Patient with anti‐ adalimumab antibodies (n = 21) | Patients without anti‐adalimumab antibodies (n = 100) | |
|---|---|---|---|
| Age (years) | 53 (13) | 51 (16) | 54 (12) |
| Female | 95 (79%) | 17 (81%) | 78 (78%) |
| DMARD treatment | |||
| Prior DMARDs | 3.6 (1.6) | 3.4 (1.6) | 3.7 (1.6) |
| Prior biologicals | 34 (28%) | 10 (48%) | 24 (24%) |
| Methotrexate use | 95 (79%) | 11 (52%) | 84 (84%) |
| Methotrexate dose (mg/week) | 19.4 (7.4) | 17.0 (8.6) | 19.7 (7.3) |
| Methotrexate plus other DMARD use | 14 (12%) | 1 (5%) | 13 (13%) |
| No concomitant DMARD | 24 (20%) | 9 (43%) | 15 (15%) |
| Prednisone use | 41 (34%) | 9 (43%) | 32 (32%) |
| Prednisone dose (mg/day) | 7.9 (4.3) | 7.1 (2.3) | 8.1 (4.7) |
| Disease status | |||
| Disease duration (years) | 12 (10) | 11 (8) | 12 (11) |
| Rheumatoid factor positive | 93 (77%) | 16 (76%) | 77 (77%) |
| Erosive disease | 94 (78%) | 18 (86%) | 77 (77%) |
| Nodular disease | 29 (24%) | 5 (24%) | 24 (24%) |
| Erythrocyte sedimentation rate (mm/h) | 32 (25) | 42 (34) | 30 (23) |
| C reactive protein (mg/dl) | 24 (28) | 34 (38) | 22 (24) |
| DAS28 | 5.3 (1.1) | 5.5 (1.2) | 5.3 (1.1) |
DAS28, disease activity score in 28 joints; DMARD, disease‐modifying anti‐rheumatic drug.
Values are mean (SD) or number (%).